• Christina Brockamp, Rüdiger Landgraf, Ulrich Alfons Müller, Dirk Müller-Wieland, Frank Petrak, Til Uebel, and the National Disease Management Guideline Group.
• Agency for Quality in Medicine (AZQ), Berlin, Germany; German Diabetes Foundation (DDS), Düsseldorf, Germany; Medical Practice for Endocrinology and Diabetology, Jena, MVZ Dr. med. Kielstein Ambulante Medizinische Versorgung GmbH Erfurt, Germany; Department of Medicine I, University Hospital RWTH Aachen, Germany; Department of Psychosomatic Medicine and Psychotherapy, LWL-University Clinic Bochum, Ruhr-University Bochum, Germany; Center for Psychotherapy Wiesbaden MVZ GmbH; Primary physicians' offices Ittlingen and Neckargmünd, Germany, Specialists in diabetology.
• Dtsch Arztebl Int. 2023 Nov 24; 120 (47): 804810804-810.

BackgroundType 2 diabetes is one of the most important widespread diseases worldwide. In Germany, nearly one in five persons over age 65 has type 2 diabetes. The German National Disease Management Guideline for Type 2 Diabetes (NDMG; in German: Nationale Versorgungsleitlinie, NVL) contains updated recommendations for the diagnostic evaluation and pharmacotherapy of this disease as well as information about specific groups of people for whom early detection may be useful.MethodsThe guideline has been updated, chapter by chapter, since 2018. Its recommendations are based on systematically searched and evaluated scientific evidence, the clinical expertise of a multidisciplinary panel of experts, and patient perspectives.ResultsThe new chapter on shared decision making includes a description of a structured approach that can be used when individual treatment goals have not been achieved. The diagnosis of diabetes newly requires at least two abnormally elevated laboratory values: e.g., fasting plasma glucose ≥ 126 mg/dL (≥ 7.0 mmol/L), HbA1c ≥ 6.5 % (≥ 48 mmol/mol) and/or casual plasma glucose ≥ 200 mg/dL (≥ 11.1 mmol/L). Cardiovascular and renal risks are to be considered in the choice of drug. Studies have shown that, in persons with cardiovascular disease, treatment with GLP-1 receptor agonists (GLP-1, glucagon-like peptide-1) or SGLT2 inhibitors (SGLT2, sodium-glucose co-transporter-2) was less likely than the comparison intervention to lead to certain patient-relevant endpoints, including all-cause mortality (OR = 0.88 and 0.84, respectively), hospitalization for heart failure (SGLT2 inhibitors: OR = 0.65), and worsening of renal function (OR = 0.61 and 0.59, respectively).ConclusionCurrent evidence continues to support the recommendations on pharmacotherapy of the 2021 guideline. The Guideline Group did not find evidence of adequate certainty to inform recommendations about the screening of persons at risk, HbA1c target values, or screening for sequelae and comorbidities. Better evidence on these matters would be desirable.

29 keywords...

hide…